Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-625 (Maralixibat) in Alagille Syndrome
NCT05543174Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of maralixibat in Alagille syndrome (ALGS), sponsored by Takeda. Started Jan 2023; status: completed.
02
Drugs
maralixibat
03
Conditions
Alagille syndrome (ALGS)
Beyond the preview
Go deeper on NCT05543174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05543174.